Individuals who previously received pertuzumab are of major clinical interest, as recommendations indicate that conventional care for the initial treatment of metastatic HER2-positive breast cancer is simultaneous HER2-blockade with trastuzumab and pertuzumab along with chemotherapy [38]. The gene discussed is ERBB2; the disease is breast carcinoma.